WallStreetZen

NYSE: TDOC
Teladoc Health Inc Stock Forecast, Predictions & Price Target

Analyst price target for TDOC

Based on 15 analysts offering 12 month price targets for Teladoc Health Inc.
Min Forecast
$153.00+13.42%
Avg Forecast
$228.33+69.26%
Max Forecast
$300.00+122.39%

Should I buy or sell TDOC stock?

Based on 16 analysts offering ratings for Teladoc Health Inc.
Buy
Strong Buy
5 analysts 31.25%
Buy
6 analysts 37.5%
Hold
5 analysts 31.25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

TDOC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Cowen & Co.
Top 50%
51
BuyMaintains$188.00+39.36%2021-08-09
Argus Research
Top 28%
73
HoldDowngradesN/AN/A2021-08-02
Deutsche Bank
Top 15%
86
HoldDowngrades$153.00+13.42%2021-07-28
Oppenheimer
Top 28%
73
BuyMaintains$220.00+63.08%2021-07-28
Needham
Top 2%
99
BuyMaintains$205.00+51.96%2021-07-28
SVB Leerink
Top 16%
85
BuyMaintains$218.00+61.60%2021-07-28
KeyBanc
Top 7%
94
Strong BuyMaintains$180.00+33.43%2021-07-28
Anonymous
Baird
HoldInitiates Coverage On$162.00+20.09%2021-05-28
Credit Suisse
Bottom 4%
4
BuyMaintains$264.00+95.70%2021-04-30
Canaccord Genuity
Top 27%
74
Strong BuyMaintains$295.00+118.68%2021-04-29

1 of 2

Forecast return on equity

Is TDOC forecast to generate an efficient return?
Company
-0.47%
Industry
12.41%
Market
1,975.18%

Forecast return on assets

Is TDOC forecast to generate an efficient return on assets?
Company
-0.42%
Industry
7.15%
Market
951.37%

TDOC earnings per share forecast

What is TDOC's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
-$3.44-49.34%
Avg 2 year Forecast
-$1.59-76.58%
Avg 3 year Forecast
-$0.47-93.08%

TDOC revenue forecast

What is TDOC's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$2.0B+23.33%
Avg 2 year Forecast
$2.6B+60.83%
Avg 3 year Forecast
$3.4B+107.66%
TDOC's revenue is forecast to grow at an exceptional rate of 27.58% per year
Forecast

TDOC revenue growth forecast

How is TDOC forecast to perform vs Health Information Services companies and vs the US market?
Company
27.58%
Industry
16.53%
Market
12.38%
TDOC's revenues are forecast to grow faster (27.58% per year) than the US Health Information Services industry average (16.53%)
Forecast
TDOC's revenues are forecast to grow faster (27.58% per year) than the US market average (12.38%)
Forecast

Teladoc Health Stock Forecast FAQ

Is Teladoc Health Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NYSE: TDOC) stock is to Buy TDOC stock.

Out of 16 analysts, 5 (31.25%) are recommending TDOC as a Strong Buy, 6 (37.5%) are recommending TDOC as a Buy, 5 (31.25%) are recommending TDOC as a Hold, 0 (0%) are recommending TDOC as a Sell, and 0 (0%) are recommending TDOC as a Strong Sell.

What is TDOC's earnings growth forecast for 2021-2023?

(NYSE: TDOC) Teladoc Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 16.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.62%.

Teladoc Health's earnings in 2021 is -$763,319,000.On average, 7 Wall Street analysts forecast TDOC's earnings for 2021 to be $-547,813,904, with the lowest TDOC earnings forecast at $-562,146,245, and the highest TDOC earnings forecast at $-535,074,046. On average, 10 Wall Street analysts forecast TDOC's earnings for 2022 to be $-253,204,683, with the lowest TDOC earnings forecast at $-515,964,259, and the highest TDOC earnings forecast at $-127,398,582.

In 2023, TDOC is forecast to generate $-74,846,667 in earnings, with the lowest earnings forecast at $-229,317,448 and the highest earnings forecast at $15,924,823.

What is TDOC's revenue growth forecast for 2021-2023?

(NYSE: TDOC) Teladoc Health's forecast annual revenue growth rate of 27.58% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 16.53%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 12.38%.

Teladoc Health's revenue in 2021 is $1,628,947,000.On average, 3 Wall Street analysts forecast TDOC's revenue for 2021 to be $319,935,741,485, with the lowest TDOC revenue forecast at $318,862,726,924, and the highest TDOC revenue forecast at $320,676,564,241. On average, 9 Wall Street analysts forecast TDOC's revenue for 2022 to be $417,191,660,041, with the lowest TDOC revenue forecast at $406,307,680,650, and the highest TDOC revenue forecast at $424,794,648,190.

In 2023, TDOC is forecast to generate $538,673,693,026 in revenue, with the lowest revenue forecast at $529,377,736,964 and the highest revenue forecast at $557,241,399,418.

What is TDOC's forecast return on assets (ROA) for 2021-2024?

(NYSE: TDOC) forecast ROA is N/A, which is lower than the forecast US Health Information Services industry average of 8.88%.

What is TDOC's Price Target?

According to 15 Wall Street analysts that have issued a 1 year TDOC price target, the average TDOC price target is $228.33, with the highest TDOC stock price forecast at $300.00 and the lowest TDOC stock price forecast at $153.00.

On average, Wall Street analysts predict that Teladoc Health's share price could stay at $228.33 by Aug 9, 2022. The average Teladoc Health stock price prediction forecasts a potential downside of N/A from the current TDOC share price of $134.90.

What is TDOC's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: TDOC) Teladoc Health's current Earnings Per Share (EPS) is -$6.79. On average, analysts forecast that TDOC's EPS will be $-3.44 for 2021, with the lowest EPS forecast at $-3.53, and the highest EPS forecast at $-3.36. On average, analysts forecast that TDOC's EPS will be $-1.59 for 2022, with the lowest EPS forecast at $-3.24, and the highest EPS forecast at $-0.80. In 2023, TDOC's EPS is forecast to hit $-0.47 (min: $-1.44, max: $0.10).

What is TDOC's forecast return on equity (ROE) for 2021-2024?

(NYSE: TDOC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.